Investing Profile

Aaron Royston

InvestorVC

Managing Partner at venBio

venbio.com/aaron.htmlSan Francisco Bay Area

Your Intro Paths to Aaron Royston

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Aaron is a member of

The Wharton School Network

709 CONNECTIONS

Bain & Company Network

465 CONNECTIONS

Duke University Network

274 CONNECTIONS

Financial Services, Financial Technology, and Business Services Network

258 CONNECTIONS

Financial Services, Financial Technology, and Business Services Network

258 CONNECTIONS

Find Aaron Royston on

Current Investing Position

venBio Managing Partner

Investment Range

$20.0M - $30.0M

Sweet Spot

$25.0M

Investments On Record

Aaron Royston is on these Sector & Stage Rankings

Pharmaceuticals (Seed)BioTech (Series B)BioTech (Seed)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series A)Health IT (Series A)Health & Hospital Services (Series B)Health & Hospital Services (Series A)San Francisco Bay Area Digital Health (Series B)Health IT (Seed)Health IT (Series B)Digital Health (Series A)Digital Health (Seed)Health & Hospital Services (Seed)

Aaron Royston's Investments On Record (12)

Company	StageDateRound Size	Total Raised
Attovia Therapeutics	Series CApr 2025$90M Series BMay 2024$110M Series AJun 2023$60M	$260M
Co-investors: James N. Topper (Xelas Consulting LLC)
Marea Therapeutics	Series BJun 2024$190M	$260M
Co-investors: Charles Homcy (Third Rock Ventures), Jeffrey Tong (Third Rock Ventures), Maha Katabi (Sofinnova Investments), Chris Garabedian (Perceptive Advisors)
Ceptur Therapeutics	Series AJan 2022$75M	$75M
Ablaze Pharmaceuticals	Series ANov 2021$75M	$75M
Co-investors: Hongbo Lu (Lilly Asia Ventures)
HistoWiz	Series AOct 2021$32M	$32M
Co-investors: Nathan Dau (Vivo Capital), Evan Cheng (Mysten Labs)
INBRACE	Series DSep 2021$100M Series COct 2019$45M	$150M
Co-investors: Peter Moldt (Novo Ventures), Joseph Siletto (Vivo Capital)
Neurogastrx	Series BAug 2021$60M Series AJan 2018$45M	$110M
Co-investors: Klaus Veitinger (OrbiMed), David Allison (Westlake Village BioPartners)
RayzeBio	Series CJun 2021$110M Series BDec 2020$110M Series AOct 2020$45M	$420M
Co-investors: Jerel Davis (Versant Ventures), bong koh (Beta Bridge Capital), Bong Koh (Venrock), Maha Katabi (Sofinnova Investments), Mike Dybbs (Samsara BioCapital)

Aaron Royston's Experience

Clinical Research Coordinator The Mount Sinai HospitalPresent

Consultant Bain & CompanyPresent

Senior Associate VIVO CapitalPresent

Board of Directors Apellis PharmaceuticalsPresent

Board Of Directors Impel NeuroPharmaPresent

Board Of Directors Financial Services, Financial Technology, and Business ServicesPresent

Board Of Directors Harmony BiosciencesPresent

Board Of Directors Neurogastrx, Inc.Present

Board Of Directors Akero TherapeuticsPresent

Board of Directors RayzeBioPresent

Board of Directors Ventyx BiosciencesPresent

Board of Directors HistoWizPresent

Board of Directors Ablaze PharmaceuticalsPresent

Board of Directors 35PharmaPresent

Board of Directors Attovia TherapeuticsPresent

Board of Directors VicebioPresent

Board of Directors Candid TherapeuticsPresent

Marrow Therapeutics Board of DirectorsPresent

Founder Financial Services, Financial Technology, and Business ServicesPresent

Managing Partner venBioPresent

Aaron Royston's Education

Duke University B.S. Biological Sciences

The Wharton School Master of Business Administration (M.B.A.) Health/Health Care Administration/Management

Investors who invest with Aaron Royston

Scouts & Angels Affiliated With Aaron Royston